|
11,676
|
| 117762 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
|
| 119246 |
ACE2
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolytic activity of ADAM17
|
|
24227843
|
Immunological
SARS-CoV infection
|
|
11,748
|
| 116392 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolysis
|
|
32333398
|
COVID-19
|
|
11,841
|
| 116921 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolytic cleavage
|
|
32264791
|
COVID-19
SARS-CoV infection
|
|
11,846
|
| 116942 |
DPC 333
|
|
decreases_quantity of
|
ACE2, soluble
|
implicating ADAM17
|
| 116943 |
cellular response to ionomycin
|
|
increases_quantity of
|
ACE2, soluble
|
supporting that ADAM17 and ADAM10 regulate ACE2 cleavage
|
| 116944 |
ACE2, soluble
|
|
decreases_activity of
|
viral entry into host cell
|
|
| 116947 |
ACE2, soluble
|
|
interacts (colocalizes) with
|
SARS-CoV S protein
|
|
| 116949 |
12-O-Tetradecanoylphorbol 13-acetate
|
|
increases_quantity of
|
ACE2, soluble
|
supporting that ADAM17 and ADAM10 regulate ACE2 cleavage
|
| 116950 |
Endotoxin
|
|
increases_quantity of
|
ACE2, soluble
|
supporting that ADAM17 and ADAM10 regulate ACE2 cleavage
|
| 116951 |
IL1B
|
|
increases_quantity of
|
ACE2, soluble
|
supporting that ADAM17 and ADAM10 regulate ACE2 cleavage
|
| 116952 |
TNF
|
|
increases_quantity of
|
ACE2, soluble
|
supporting that ADAM17 and ADAM10 regulate ACE2 cleavage
|
| 116956 |
ACE2 shedding
|
|
increases_quantity of
|
ACE2, soluble
|
|
| 121046 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
in primary human airway epithelial cells
|
|
19411314
|
SARS-CoV infection
|
|
11,847
|
| 133579 |
SARS-CoV S protein
|
|
increases_quantity of
|
ACE2, soluble
|
in the supernatant
|
|
18490652
|
SARS-CoV infection
|
|
11,849
|
| 117001 |
Calmodulin inhibitor
|
|
increases_quantity of
|
ACE2, soluble
|
inhibitors of calmodulin increase the release of the ACE2 ectodomain
|
|
18070603
|
SARS-CoV infection
|
|
11,899
|
| 117136 |
ACE2, soluble
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in cerebrospinal fluid
|
| 117156 |
hypertension
|
|
increases_activity of
|
ACE2, soluble
|
in cerebrospinal fluid
|
| 117157 |
ACE2, soluble
|
|
decreases_quantity of
|
Angiotensin II
|
in cerebrospinal fluid
|
|
28512108
|
Neurological
SARS-CoV infection
|
|
11,924
|
| 133119 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma
|
|
24332999
|
Endocrine
|
|
12,014
|
| 117709 |
ACE2, soluble
|
NOT |
affects_activity of
|
inflammatory response
|
|
| 117733 |
ACE2, soluble
|
|
increases_activity of
|
systolic dysfunction
|
|
| 117734 |
ACE2, soluble
|
|
increases_activity of
|
heart failure
|
|
|
19700132
|
Cardiovascular disease
|
|
12,015
|
| 117710 |
ACE2, soluble
|
|
affects_activity of
|
heart failure, acute decompensated
|
after treatment
|
|
24054336
|
Cardiovascular disease
|
|
12,207
|
| 119892 |
ACE2, soluble
|
|
interacts (colocalizes) with
|
SARS-CoV-2 S protein
|
|
|
32294179
|
Diabetes mellitus, type II
Insulin resistance
COVID-19
|
|
12,364
|
| 121098 |
ACE2, soluble
|
|
decreases_activity of
|
SARS-CoV S protein
|
concerning the binding of the SARS-CoV spike protein to its receptor
|
| 121099 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
via shedding
|
|
15983030
|
SARS-CoV infection
|
CIDeR